Efficacy of Long-Acting Bedaquiline Regimens in a Mouse Model of Tuberculosis Preventive Therapy
- 1 March 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 205 (5) , 570-579
Abstract
Rationale: Completion of preventive therapy is a major bottleneck in global tuberculosis control. Long-acting injectable drug formulations would shorten therapy administration and may thereby improve completion rates. Recently, a long-acting formulation of bedaquiline demonstrated antituberculosis activity for up to 12 weeks after injection in a validated mouse model of preventive therapy. Objectives: The objectives of this study were to 1) determine the total duration of activity after an injection of long-acting bedaquiline and 2) evaluate the activity of regimens comprised of long-acting bedaquiline plus short (2–4 wk) oral companion courses of bedaquiline, with or without rifapentine, using the validated mouse model of tuberculosis preventive therapy. Methods: After the establishment of a stable Mycobacterium tuberculosislung infection in bacillus Calmette-Guérin (BCG)-immunized BALB/c mice, treatment was initiated with 1 of 12 randomly assigned regimens. In addition to positive and negative controls, six regimens included one or two injections of long-acting bedaquiline (alone or with oral bedaquiline with or without rifapentine), and four comparator regimens consisted of oral agents only. Lung bacterial burden was measured monthly for up to 28 weeks. Measurements and Main Results: One injection of long-acting bedaquiline at 160 mg/kg exerted antituberculosis activity for 12 weeks. Compared with the positive control (daily isoniazid-rifapentine for 4 wk), six regimens had equivalent bactericidal activity (including two all-oral comparator regimens), and two regimens had superior sterilizing activity: one injection with 2 weeks of oral bedaquiline and high-dose rifapentine; and two injections with 4 weeks of oral bedaquiline. Conclusions: Long-acting injectable bedaquiline has significant potential for shortening tuberculosis preventive therapy.Keywords
This publication has 23 references indexed in Scilit:
- Dose-Ranging Comparison of Rifampin and Rifapentine in Two Pathologically Distinct Murine Models of TuberculosisAntimicrobial Agents and Chemotherapy, 2012
- Pharmacokinetics and Pharmacodynamics of TMC207 and Its N -Desmethyl Metabolite in a Murine Model of TuberculosisAntimicrobial Agents and Chemotherapy, 2012
- Sterilizing Activity of Novel TMC207- and PA-824-Containing Regimens in a Murine Model of TuberculosisAntimicrobial Agents and Chemotherapy, 2011
- Short-Course Chemotherapy with TMC207 and Rifapentine in a Murine Model of Latent Tuberculosis InfectionAmerican Journal of Respiratory and Critical Care Medicine, 2011
- Short-Course Therapy with Daily Rifapentine in a Murine Model of Latent Tuberculosis InfectionAmerican Journal of Respiratory and Critical Care Medicine, 2009
- Paradoxical Effect of Isoniazid on the Activity of Rifampin-Pyrazinamide Combination in a Mouse Model of TuberculosisAntimicrobial Agents and Chemotherapy, 2009
- Mechanisms Underlying the Increased Susceptibility of Aged Mice to TuberculosisNutrition Reviews, 2009
- Using Animal Models to Develop New Treatments for TuberculosisSeminars in Respiratory and Critical Care Medicine, 2008
- MICROBIAL PERSISTENCEJournal of Experimental Medicine, 1966
- FATE OF MYCOBACTERIUM TUBERCULOSIS IN MOUSE TISSUES AS DETERMINED BY THE MICROBIAL ENUMERATION TECHNIQUEJournal of Experimental Medicine, 1956